Noliprel

Leaflet accompanying the packaging: patient information

Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.

Noliprel (Noliprel Arginine), 2.5 mg + 0.625 mg, film-coated tablets
Perindopril arginine + Indapamide
Noliprel and Noliprel Arginine are different trade names for the same drug.

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet so that you can read it again if you need to.
• If you have any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet:

• 1. What is Noliprel and what is it used for
• 2. Important information before taking Noliprel
• 3. How to take Noliprel
• 4. Possible side effects
• 5. How to store Noliprel
• 6. Contents of the packaging and other information

1. What is Noliprel and what is it used for

Noliprel is a combination medicine that contains two active substances: perindopril and indapamide.
It is an antihypertensive medicine used to treat high blood pressure in adults.
Perindopril belongs to a group of medicines called angiotensin-converting enzyme inhibitors (ACE inhibitors). These medicines work by widening blood vessels, making it easier for the heart to pump blood.
Indapamide is a diuretic. Diuretics increase the amount of urine excreted by the kidneys. Indapamide differs from other diuretics in that it only slightly increases urine excretion.
Both active substances lower blood pressure and work together to normalize the patient's blood pressure.

2. Important information before taking Noliprel

When not to take Noliprel:

• if the patient is allergic to perindopril or other ACE inhibitors, to indapamide or other sulfonamides, or to any of the other ingredients of this medicine (listed in section 6);
• if the patient has experienced symptoms such as wheezing, swelling of the face or tongue, intense itching, or severe skin rash while taking an ACE inhibitor in the past, or if such symptoms have occurred in the patient or a relative in any other circumstances (a condition called angioedema);
• if the patient has diabetes or kidney problems and is being treated with a blood pressure-lowering medicine containing aliskiren;
• if the patient has severe liver disease or a condition called hepatic encephalopathy (a disease that damages the brain);
• if the patient has severe kidney disease that reduces blood flow to the kidneys (renal artery stenosis);
• if the patient is undergoing dialysis or blood filtration using a method other than hemodialysis. Depending on the device used, Noliprel may not be suitable for the patient.
• if the patient has low potassium levels in the blood;
• if the patient has untreated, uncontrolled heart failure (severe water retention, difficulty breathing);
• if the patient is pregnant over 3 months (it is also recommended to avoid taking Noliprel in early pregnancy - see "Pregnancy");
• if the patient has taken or is currently taking a combination medicine containing sacubitril and valsartan, used to treat heart failure, as the risk of angioedema (rapid swelling of tissues under the skin in the throat area) increases (see "Warnings and precautions" and "Noliprel and other medicines").

Warnings and precautions

Before starting to take Noliprel, the patient should discuss it with their doctor or pharmacist:

• if the patient has a narrowing of the aortic valve (narrowing of the main blood vessel carrying blood from the heart) or hypertrophic cardiomyopathy (a disease of the heart muscle) or renal artery stenosis (narrowing of the blood vessel supplying blood to the kidney);
• if the patient has heart failure or any other heart disease;
• if the patient has kidney disease or is undergoing dialysis;
• if the patient experiences vision loss or eye pain. These may be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or increased pressure in the eye, which may occur within a few hours or weeks of taking Noliprel. Untreated symptoms can lead to permanent vision loss. If the patient has previously been allergic to penicillin or sulfonamides, there is a greater risk of these disorders.
• if the patient has muscle disorders, including pain, tenderness, weakness, or muscle cramps;
• if the patient has an abnormally high level of a hormone called aldosterone in the blood (primary aldosteronism);
• if the patient has liver disease;
• if the patient has collagenosis (a skin disease), such as systemic lupus erythematosus or scleroderma;
• if the patient has atherosclerosis (hardening of the arteries);
• if the patient has hyperparathyroidism (a disorder of parathyroid function);
• if the patient has gout;
• if the patient has diabetes;
• if the patient is on a low-salt diet or uses salt substitutes containing potassium;
• if the patient is taking lithium or potassium-sparing medicines (spironolactone, triamterene), or potassium supplements, they should be avoided while taking Noliprel (see "Noliprel and other medicines");
• if the patient is elderly;
• if the patient has had allergic reactions to light;
• if the patient experiences a severe allergic reaction with swelling of the face, lips, mouth, tongue, or throat, which can cause difficulty swallowing or breathing (angioedema)
• swelling may occur at any time during treatment. If such symptoms occur, treatment should be discontinued and the doctor should be consulted immediately;
• if the patient is taking any of the following medicines used to treat high blood pressure:
• angiotensin II receptor antagonist (AIIRA), also known as a sartan - e.g., valsartan, telmisartan, irbesartan, especially if the patient has diabetic nephropathy;
• aliskiren. The doctor may recommend regular monitoring of kidney function, blood pressure, and electrolyte levels (e.g., potassium) in the blood. See also the subsection "When not to take Noliprel".
• if the patient is black - in this case, there may be a greater risk of angioedema and the medicine may be less effective in lowering blood pressure than in patients of other races;
• if the patient is undergoing dialysis using high-flux membranes;
• if the patient is taking any of the following medicines, which increase the risk of angioedema:
• racecadotril (used to treat diarrhea);
• sirolimus, everolimus, temsirolimus, and other medicines belonging to the group of medicines called mTOR inhibitors (used to prevent organ rejection and treat cancer);
• sacubitril (available in a combination medicine containing sacubitril and valsartan), used to treat chronic heart failure;
• linagliptin, saxagliptin, sitagliptin, wildagliptin, and other medicines belonging to the group of medicines called gliptins (used to treat diabetes).

Angioedema
In patients treated with ACE inhibitors, including Noliprel, angioedema (a severe allergic reaction with swelling of the face, lips, tongue, or throat, and difficulty swallowing or breathing) has been reported. This reaction can occur at any time during treatment. If the patient experiences such symptoms, they should stop taking Noliprel and contact their doctor immediately. See also section 4.
The patient should tell their doctor about pregnancy, suspected pregnancy, or planned pregnancy. The doctor will usually recommend stopping Noliprel before becoming pregnant or as soon as the patient finds out they are pregnant, and will recommend a different medicine instead of Noliprel. Noliprel should not be taken during early pregnancy and should not be taken after 3 months of pregnancy, as it may cause serious harm to the baby (see "Pregnancy and breastfeeding").
When taking Noliprel, the patient should also inform their doctor or medical staff:

• if the patient is to be anesthetized and/or undergo surgery;
• if the patient has recently experienced diarrhea or vomiting, or is dehydrated;
• if the patient is to undergo dialysis or LDL apheresis (removal of cholesterol from the blood using a special device);
• if the patient is to undergo desensitization treatment to reduce allergic reactions to bee or wasp stings;
• if the patient is to undergo a test that requires the administration of a contrast agent containing iodine (a substance that allows organs such as the kidney or stomach to be seen on an X-ray);
• if the patient experiences vision loss or pain in one or both eyes while taking Noliprel. These may be symptoms of glaucoma or increased pressure in the eye. The patient should stop taking Noliprel and consult their doctor.

Athletes should be aware that Noliprel contains an active substance (indapamide) that may cause a positive result in a doping test.

Children and adolescents

Noliprel should not be taken by children and adolescents.

Noliprel and other medicines

The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
The patient should avoid taking Noliprel with:

• lithium (used to treat mania or depression);
• aliskiren (a medicine used to treat high blood pressure) in patients who do not have diabetes or kidney problems;
• potassium-sparing diuretics (e.g., triamterene, amiloride), potassium salts, or other medicines that may increase potassium levels in the body (such as heparin, a medicine used to thin the blood and prevent clot formation; trimethoprim and cotrimoxazole, also known as a combination medicine containing trimethoprim and sulfamethoxazole, used to treat bacterial infections);
• estramustine (used to treat cancer);
• other medicines used to treat high blood pressure: ACE inhibitors and angiotensin II receptor antagonists.

Taking other medicines may affect treatment with Noliprel. The doctor may recommend changing the dose and/or taking other precautions. The patient should tell their doctor about taking any of the following medicines, as special precautions may be necessary:

• other medicines used to treat high blood pressure, including angiotensin II receptor antagonists (AIIRA) or aliskiren (see also subsections "When not to take Noliprel" and "Warnings and precautions"), or diuretics (medicines that increase urine excretion);
• potassium-sparing medicines used to treat heart failure: eplerenone and spironolactone in doses of 12.5 mg to 50 mg per day;
• medicines commonly used to treat diarrhea (racecadotril) or to prevent organ rejection (sirolimus, everolimus, temsirolimus, and other medicines belonging to the group of medicines called mTOR inhibitors). See the "Warnings and precautions" section.
• a combination medicine containing sacubitril and valsartan (used to treat chronic heart failure). See the "When not to take Noliprel" and "Warnings and precautions" sections.
• anesthetics;
• iodine-containing contrast agents;
• antibiotics used to treat bacterial infections (e.g., moxifloxacin, sparfloxacin, erythromycin given by injection);
• methadone (used to treat addiction);
• procainamide (used to treat heart rhythm disorders);
• allopurinol (used to treat gout);
• antihistamines used to treat allergic reactions, such as hay fever (e.g., mizolastine, terfenadine, astemizole);
• corticosteroids used to treat various diseases, including severe asthma and rheumatoid arthritis;
• immunosuppressive medicines used to treat autoimmune diseases or after organ transplantation to prevent rejection (e.g., cyclosporine, tacrolimus);
• halofantrine (used to treat certain types of malaria);
• pentamidine (used to treat pneumonia);
• gold salts given by injection (used to treat rheumatoid arthritis);
• vinkamine (used to treat cognitive impairment in the elderly, including memory loss);
• bepridil (used to treat angina pectoris);
• medicines used to treat heart rhythm disorders (e.g., quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, digitalis preparations, bretylium);
• cisapride, difemanil (used to treat gastrointestinal disorders);
• digoxin or other cardiac glycosides (used to treat heart diseases);
• baclofen (used to treat muscle stiffness in diseases such as multiple sclerosis);
• medicines used to treat diabetes, such as insulin, metformin, or gliptins;
• calcium, including calcium supplements;
• laxatives with a stimulating effect (e.g., senna);
• non-steroidal anti-inflammatory medicines (e.g., ibuprofen) or high doses of salicylates (e.g., acetylsalicylic acid (a substance found in many medicines, used as a pain reliever and antipyretic, as well as to prevent blood clot formation));
• amphotericin B given by injection (used to treat severe fungal infections);
• medicines used to treat mental disorders, such as depression, anxiety, schizophrenia (e.g., tricyclic antidepressants, neuroleptics (such as amisulpride, sulpiride, sultopride, tiapride, haloperidol, droperidol));
• tetracosactide (used to treat Crohn's disease);
• trimethoprim (used to treat infections);
• vasodilators, including nitrates;
• medicines used to treat low blood pressure, shock, or asthma (e.g., ephedrine, norepinephrine, or epinephrine).

Noliprel with food and drink

Noliprel should be taken before a meal.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine.

Pregnancy

The patient should inform their doctor about pregnancy, suspected pregnancy, or planned pregnancy. The doctor will usually recommend stopping Noliprel before becoming pregnant or as soon as the patient finds out they are pregnant, and will recommend a different medicine instead of Noliprel. Noliprel should not be taken during early pregnancy and should not be taken after 3 months of pregnancy, as it may cause serious harm to the baby.

Breastfeeding

Noliprel should not be taken if the patient is breastfeeding.
The patient should immediately tell their doctor if they are breastfeeding or plan to breastfeed.
The patient should contact their doctor immediately.

Driving and using machines

Noliprel usually does not affect the ability to drive or use machines, however, some patients may experience dizziness or fatigue related to low blood pressure.
In such cases, the ability to drive or use machines may be impaired.

Noliprel contains lactose monohydrate

If the patient has been diagnosed with intolerance to some sugars, they should contact their doctor before taking this medicine.

Noliprel contains sodium

Noliprel contains less than 1 mmol of sodium (23 mg) per tablet, which means that the medicine is considered "sodium-free".

3. How to take Noliprel

This medicine should always be taken exactly as prescribed by the doctor or pharmacist.
If the patient has any doubts, they should consult their doctor or pharmacist.
The recommended dose is one tablet per day. The doctor may decide to increase the dose to 2 tablets per day or modify the dosing regimen in case of kidney problems.
The tablet should be taken preferably in the morning, before a meal. The tablet should be swallowed with a glass of water.
The score line on the tablet is not intended for breaking the tablet.

Taking a higher dose of Noliprel than recommended

If the patient has taken too many tablets, they should immediately contact their doctor or go to the emergency department of the nearest hospital. The most common symptom of overdose is low blood pressure.
If the patient experiences significantly low blood pressure (with accompanying nausea, vomiting, cramps, dizziness, drowsiness, disorientation, and changes in urine excretion), they may be helped by lying down with their legs raised.

Missing a dose of Noliprel

It is important to take the medicine every day, as regular treatment is most effective.
If the patient misses a dose of Noliprel, they should take the next dose at the usual time.
The patient should not take a double dose to make up for the missed dose.

Stopping treatment with Noliprel

Treatment of high blood pressure is long-term, so before stopping treatment with this medicine, the patient should contact their doctor.
If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.

4. Possible side effects

Like all medicines, Noliprel can cause side effects, although not everybody gets them.

If the patient experiences any of the following side effects, which may be serious, they should stop taking this medicine and contact their doctor immediately:

• severe dizziness or fainting due to low blood pressure (often - may occur in less than 1 in 10 patients);
• bronchospasm (feeling of compression in the chest, wheezing, and shortness of breath; uncommon - may occur in less than 1 in 100 patients);
• swelling of the face, lips, mouth, tongue, or throat, difficulty breathing (angioedema, see the subsection "Warnings and precautions" in section 2); uncommon - may occur in less than 1 in 100 patients;
• severe skin reactions, including erythema multiforme (a skin rash often starting with the appearance of red, itchy spots on the face, arms, or legs) or severe skin rash, hives, redness of the skin all over the body, severe itching, blistering, peeling, and swelling of the skin, inflammation of the mucous membranes (Stevens-Johnson syndrome) or other allergic reactions (very rare - may occur in less than 1 in 10,000 patients);
• cardiovascular disorders (heart rhythm disorders, angina pectoris (chest pain radiating to the jaw and back, caused by physical exertion), myocardial infarction; very rare - may occur in less than 1 in 10,000 patients);
• weakness or numbness of the arms or legs, or speech disorders, which may be symptoms of a stroke (very rare - may occur in less than 1 in 10,000 patients);
• pancreatitis, which may cause severe abdominal pain and very poor general condition (very rare - may occur in less than 1 in 10,000 patients);
• jaundice (yellowing of the skin or eyes), which may be a symptom of hepatitis (very rare - may occur in less than 1 in 10,000 patients);
• life-threatening heart rhythm disorders (frequency not known);
• liver disease caused by liver disease (hepatic encephalopathy; frequency not known);
• muscle weakness, cramps, tenderness, or pain, especially if the patient feels unwell or has a high fever, which may be caused by abnormal muscle breakdown (frequency not known).

Side effects, grouped by decreasing frequency, may include:

• common (may occur in less than 1 in 10 patients): low potassium levels in the blood, skin reactions in patients prone to allergic and asthmatic reactions, headache, dizziness of central origin, dizziness of labyrinthine origin, tingling sensation, vision disturbances, tinnitus (feeling of hearing sounds), cough, shortness of breath, gastrointestinal disorders (nausea, vomiting, abdominal pain, taste disturbances, indigestion or digestive disorders, diarrhea, constipation), allergic reactions (such as skin rashes, itching), muscle cramps, fatigue.
• uncommon (may occur in less than 1 in 100 patients): mood swings, depression, sleep disturbances, hives, purpura (red spots on the skin), clusters of blisters, kidney disease, impotence (inability to achieve or maintain an erection), increased sweating, increased eosinophil count (a type of white blood cell), changes in laboratory test results: high potassium levels in the blood, which may be temporary after stopping treatment, low sodium levels in the blood, which may cause dehydration and low blood pressure, drowsiness, fainting, palpitations (feeling of heartbeats), tachycardia (fast heart rate), hypoglycemia (very low blood sugar levels) in patients with diabetes, vasculitis (inflammation of blood vessels), dryness of the mucous membranes of the mouth, hypersensitivity reactions to light, joint pain, muscle pain, chest pain, malaise, peripheral edema, fever, increased urea levels in the blood, increased creatinine levels in the blood, falls.
• rare (may occur in less than 1 in 1,000 patients): worsening of psoriasis, changes in laboratory test results: low chloride levels in the blood, low magnesium levels in the blood, increased liver enzyme activity, high bilirubin levels in the blood; fatigue, sudden reddening of the face and neck, decreased or absent urine excretion, acute kidney failure. Dark urine, nausea, or vomiting, muscle cramps, disorientation, and seizures. These may be symptoms of a condition called SIADH (inappropriate antidiuretic hormone secretion).
• very rare (may occur in less than 1 in 10,000 patients): disorientation, eosinophilic pneumonia (a rare type of pneumonia), inflammation of the nasal mucous membranes (nasal congestion or runny nose), severe kidney disease, changes in blood parameters, such as decreased white blood cell count, decreased red blood cell count, decreased hemoglobin levels, decreased platelet count, high calcium levels in the blood, liver function disorders.
• frequency not known (cannot be estimated from the available data): abnormal heart function detectable on an electrocardiogram, changes in laboratory test results: low potassium levels, high uric acid levels, and high blood sugar levels, myopia, blurred vision, vision disturbances, eye pain due to high pressure (possible symptoms of choroidal effusion or acute glaucoma), cyanosis, numbness, and pain in the fingers or toes (Raynaud's phenomenon). If the patient has systemic lupus erythematosus (a type of collagenosis), the symptoms of the disease may worsen.

There may be blood, kidney, liver, or pancreas disorders, as well as changes in laboratory test results. The doctor may recommend blood tests to monitor the patient's health.
If such symptoms occur, the patient should contact their doctor as soon as possible.

Reporting side effects

If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting side effects can help gather more information on the safety of this medicine.

5. How to store Noliprel

The medicine should be stored out of sight and reach of children.
The medicine should not be taken after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
The container should be kept tightly closed to protect it from moisture.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Noliprel contains

• The active substances of Noliprel are perindopril and indapamide. One film-coated tablet contains 2.5 mg of perindopril arginine (which corresponds to 1.6975 mg of perindopril) and 0.625 mg of indapamide.
• Other ingredients of the tablet core: lactose monohydrate, magnesium stearate, maltodextrin, colloidal silica anhydrous, sodium carboxymethylcellulose (type A); ingredients of the film coating: glycerol, hypromellose, macrogol 6000, magnesium stearate, titanium dioxide (E 171).

What Noliprel looks like and contents of the packaging

Noliprel is a white, oval, film-coated tablet with a score line on both sides. One film-coated tablet contains 2.5 mg of perindopril arginine and 0.625 mg of indapamide.
The tablets are available in packs of 30, 60, and 90.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.

Marketing authorization holder in Latvia, the country of export:

Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex, France

Manufacturer:

ANPHARM Pharmaceutical Company S.A.
ul. Annopol 6B
03-236 Warsaw, Poland
Les Laboratoires Servier Industrie
905 route de Saran
45520 Gidy, France
Servier (Ireland) Industries Ltd
Gorey Road
Arklow - Co. Wicklow, Ireland

Parallel importer:

InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw

Repackaged by:

InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in Latvia, the country of export:07-0015

Parallel import authorization number: 389/24

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

Austria
PRETERAX-ARGININ
Belgium
PRETERAX 2,5 mg/0,625 mg
Cyprus
COVERSYL PLUS ARGININE 2.5 mg/0.625 mg
Estonia
NOLIPREL ARGININE
Finland
PRETERAX NOVUM
France
PRETERAX 2,5mg/0,625mg
Germany
PRETERAX N 2,5 mg/ 0,625 mg Filmtabletten
Greece
PRETERAX 2,5 mg/0,625 mg
Ireland
COVERSYL ARGININE PLUS 2.5mg/0.625mg
Italy
PRETERAX 2,5 mg/0,625 mg
Latvia
NOLIPREL ARGININE 2.5mg/0.625mg apvalkotās tabletes
Lithuania
NOLIPREL 2,5 mg/0,625 mg tabletès
Luxembourg
PRETERAX 2,5 mg/0,625 mg
Poland
NOLIPREL
Portugal
PRETERAX 2,5 mg/0,625 mg
Romania
NOLIPREL ARG 2,5 mg/ 0,625 mg
Slovak Republic
NOLIPREL A
Slovenia
BIONOLIPREL 2.5mg/0.625mg filmsko obložene tablete
Translation of the symbols of the days of the week on the immediate packaging:

• P– Monday, O– Tuesday, T– Wednesday, C– Thursday, Pk– Friday, S– Saturday, Sv– Sunday.

Date of approval of the leaflet: 12.11.2024

[Information about the trademark]